Key result
Global longitudinal strain lacks clear prognostic value for HCM development in mutation carriers.
Why the study?
GLS is reduced in patients with HCM despite normal LVEF, but its value in individuals with HCM mutations without hypertrophic changes and its prognostic ability to predict HCM development were unknown.
Does global longitudinal strain (GLS) predict the development of hypertrophic cardiomyopathy in HCM gene mutation carriers without baseline hypertrophic changes?
Cohort (n=230)
No
Does global longitudinal strain (GLS) predict the development of hypertrophic cardiomyopathy in HCM gene mutation carriers without baseline hypertrophic changes?
Effect estimate: HR 0.78 (95% CI 0.60-1.02)
p-value: p=0.07
While global longitudinal strain is increased in HCM mutation carriers prior to the onset of hypertrophy, it does not independently predict the future development of overt hypertrophic cardiomyopathy.
GLS should not guide risk stratification in mutation carriers; leaves open its role in serial monitoring or combined models.
No takes yet. Share an insight, caveat, or question.
Velzen et al. (2019) conducted a cohort in Hypertrophic cardiomyopathy gene mutation without hypertrophic changes (n=230). Global longitudinal strain (GLS) assessment was evaluated on Development of hypertrophic cardiomyopathy (HCM) (HR 0.78, 95% CI 0.60-1.02, p=0.07). Global longitudinal strain had no clear prognostic value for the development of hypertrophic cardiomyopathy during a 5.6-year follow-up in HCM mutation carriers (HR 0.78).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: